{"id":"gefarnate","rwe":[],"tags":[{"label":"gefarnate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A02BX07","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Ulcer Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"gefarnyl","offLabel":[],"synonyms":["gefarnate","dixnalate","gefarnyl","geranyl farnesylacetate"],"timeline":[],"approvals":[],"brandName":"Gefarnyl","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"gefarnate","explanation":"Think of leukotrienes like messengers that tell your body to get inflamed. Gefarnate blocks these messengers from being made, which can help reduce inflammation and alleviate symptoms. This can be especially helpful for people with conditions like asthma or allergies.","oneSentence":"Gefarnate works by inhibiting the enzyme involved in the production of leukotrienes, which are pro-inflammatory mediators.","technicalDetail":"Gefarnate is a leukotriene synthesis inhibitor that targets the enzyme 5-lipoxygenase, which is responsible for converting arachidonic acid into leukotrienes."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1281","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GEFARNATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GEFARNATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:41:10.221623","biosimilars":[],"competitors":[{"drugName":"sucralfate","drugSlug":"sucralfate","fdaApproval":"1981-10-30","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bismuth subcitrate","drugSlug":"bismuth-subcitrate","fdaApproval":"2006-09-28","relationship":"same-class"}],"genericName":"gefarnate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"sucralfate","brandName":"sucralfate","genericName":"sucralfate","approvalYear":"1981","relationship":"same-class"},{"drugId":"bismuth-subcitrate","brandName":"bismuth subcitrate","genericName":"bismuth subcitrate","approvalYear":"2006","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03610321","phase":"PHASE2,PHASE3","title":"Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2019-09-01","conditions":["Coronary Artery Disease"],"enrollment":70,"completionDate":"2021-12-31"},{"nctId":"NCT00787254","phase":"PHASE3","title":"Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-04","conditions":["Stomach Ulcer","Duodenal Ulcer"],"enrollment":366,"completionDate":"2009-05"},{"nctId":"NCT00762359","phase":"PHASE3","title":"A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers","status":"TERMINATED","sponsor":"Takeda","startDate":"2007-05","conditions":["Stomach Ulcer","Duodenal Ulcer"],"enrollment":461,"completionDate":"2008-11"},{"nctId":"NCT01051388","phase":"PHASE3","title":"Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2008-08","conditions":["Cardio-cerebrovascular Disease"],"enrollment":280,"completionDate":"2010-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1ISE2Y6ULA","CHEBI":"CHEBI:31646","INN_ID":"1546","UMLSCUI":"C0017226","ChEMBL_ID":"CHEMBL2105085","KEGG_DRUG":"D01529","DRUGBANK_ID":"DB12079","PUBCHEM_CID":"5282182","MESH_DESCRIPTOR_UI":"D005778"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":74,"therapeuticAreas":["Respiratory"],"atcClassification":{"source":"DrugCentral","atcCode":"A02BX07","allCodes":["A02BX07","A02BX77"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gefarnate, also known as GEFARNATE, is a small molecule drug in the gefarnate class. It is a medication that has been developed to treat certain conditions, although its exact target and approved indications are not specified. The commercial status of Gefarnate is unclear, with unknown patent status and generic manufacturers. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also not available. As a result, its safety profile and potential side effects are not well-documented.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}